Pear Therapeutics announced today that Prescryptive Health will offer and administer benefit coverage for its digital therapeutics.
Boston-based Pear Therapeutics’ reSET and reSET-O, two FDA-cleared prescription digital therapeutics (PDTs) for treating substance and opioid use disorder, have been added to Prescryptive’s formularies and are being administered as standard pharmacy benefits for its members, according to a news release.
Prescryptive is set to include reSET and reSET-O on its platform to offer a seamless experience for its members in using the PDTs, which provide algorithm-driven cognitive behavioral therapy, fluency training and contingency management.
reSET is a monotherapy for patients 18 years of age or older with substance use disorder, while reSET-O is used in combination with transmucosal buprenorphine for those 18 and up with opioid use disorder. Recent analysis highlighted the cost-effectiveness and quality of life improvements provided by reSET-O.
“Prescryptive has launched the world’s first health intelligence platform powered by blockchain that delivers patients the necessary prescription information they need in real-time to their mobile device while they are engaged with their healthcare provider,” Prescryptive CEO Chris Blackley said in the release. “Teaming with Pear to make reSET and reSET-O available to our members is a natural extension of our aim to deliver empowering benefit plan solutions that inspire better health.”
“With an aligned mission to engage patients and redefine the delivery of care, we are pleased to team with Prescryptive to provide people in recovery with covered access to innovative FDA-authorized treatments through their mobile devices when and where they need it most,” added Pear Therapeutics president & CEO Dr. Corey McCann. “With this coverage decision, Pear continues to expand access to PDTs by adding reSET and reSET-O to a standard formulary.”